OncoSenX

OncoSenX is a late-stage pre-clinical biotechnology company based in Seattle, Washington, that develops non-viral gene therapies aimed at treating solid tumors. The company's platform utilizes a proprietary lipid nanoparticle (LNP) delivery system to transport a targeted DNA payload into cancerous cells. Unlike traditional chemotherapy, which often damages healthy tissue, OncoSenX’s technology is engineered to induce apoptosis, or programmed cell death, specifically within cells based on their genetic and transcriptional activity. This approach effectively uses DNA as a programmable instruction set to identify and neutralize malignant cells while sparing surrounding healthy tissue, aiming to provide a more precise and less toxic therapeutic intervention.

This technology is designed to address the significant limitations of conventional cancer treatments, particularly their associated toxicity and lack of specificity. By targeting cells based on the specific mutations they harbor, the company’s platform holds the potential to improve patient tolerability and efficacy compared to standard chemotherapies or existing biologics. A spinout of Oisin Biotechnologies, OncoSenX has focused its research on preparing for pivotal toxicology studies and human clinical trials. Its work represents an effort to move cancer therapy from traditional chemistry toward a more targeted, information-based approach to oncology.